MX2024009843A - Inhibidores de irak4. - Google Patents
Inhibidores de irak4.Info
- Publication number
- MX2024009843A MX2024009843A MX2024009843A MX2024009843A MX2024009843A MX 2024009843 A MX2024009843 A MX 2024009843A MX 2024009843 A MX2024009843 A MX 2024009843A MX 2024009843 A MX2024009843 A MX 2024009843A MX 2024009843 A MX2024009843 A MX 2024009843A
- Authority
- MX
- Mexico
- Prior art keywords
- irak4 inhibitors
- formula
- irak4
- medicine
- consequently
- Prior art date
Links
- 229940127590 IRAK4 inhibitor Drugs 0.000 title 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 abstract 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente solicitud se refiere a compuestos químicos de Fórmula (I), y sales farmacéuticamente aceptables de estos, que inhiben IRAK4 y en consecuencia tienen una posible utilidad en medicina. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263267956P | 2022-02-14 | 2022-02-14 | |
| PCT/EP2023/053416 WO2023152349A1 (en) | 2022-02-14 | 2023-02-13 | Irak4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009843A true MX2024009843A (es) | 2024-08-22 |
Family
ID=85227248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009843A MX2024009843A (es) | 2022-02-14 | 2023-02-13 | Inhibidores de irak4. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12240832B2 (es) |
| EP (1) | EP4479137A1 (es) |
| JP (2) | JP7555519B2 (es) |
| KR (1) | KR20240051921A (es) |
| CN (1) | CN118591536A (es) |
| AR (1) | AR128506A1 (es) |
| AU (1) | AU2023218575A1 (es) |
| CA (1) | CA3250704A1 (es) |
| CL (1) | CL2024002402A1 (es) |
| CO (1) | CO2024012172A2 (es) |
| CR (1) | CR20240383A (es) |
| DO (1) | DOP2024000148A (es) |
| IL (1) | IL314800A (es) |
| MX (1) | MX2024009843A (es) |
| PE (1) | PE20242100A1 (es) |
| TW (1) | TW202400574A (es) |
| UY (1) | UY40145A (es) |
| WO (1) | WO2023152349A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025036841A1 (en) | 2023-08-11 | 2025-02-20 | Astrazeneca Ab | Crystalline irak4 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3126330T (pt) | 2014-04-04 | 2019-04-29 | Pfizer | Compostos bicíclicos de heteroarilo ou arilo fusionados e a sua utilização como inibidores de irak4 |
| WO2016174183A1 (en) | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| JP2018524365A (ja) | 2015-07-15 | 2018-08-30 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Ｉｒａｋ−４阻害剤としての置換アザ化合物 |
| CN109152771B (zh) | 2016-06-01 | 2022-07-19 | 拜耳医药股份有限公司 | 2-取代的吲唑用于治疗和预防自身免疫疾病的用途 |
| WO2018234342A1 (en) | 2017-06-21 | 2018-12-27 | F. Hoffmann-La Roche Ag | ISOINDOLINONE DERIVATIVES AS MODULATORS OF IRAK4 |
| PH12021553232A1 (en) | 2019-06-27 | 2022-09-05 | Biogen Ma Inc | 2h-indazole derivatives and their use in the treatment of disease |
| MA56390A (fr) | 2019-06-27 | 2022-05-04 | Biogen Ma Inc | Dérivés d'imidazo[1,2-a]pyridinyle et leur utilisation dans le traitement d'une maladie |
| CN118146193A (zh) | 2019-09-24 | 2024-06-07 | 上海美悦生物科技发展有限公司 | 一种irak抑制剂及其制备方法和用途 |
| US11866405B2 (en) * | 2020-12-10 | 2024-01-09 | Astrazeneca Ab | Substituted indazoles as IRAK4 inhibitors |
| KR20230134500A (ko) * | 2020-12-22 | 2023-09-21 | 바이오젠 엠에이 인코포레이티드 | Irak4 억제제로서의 이미다조[1,2-a]피리딘 유도체및 질환의 치료에서의 그의 용도 |
| JP2024501281A (ja) | 2020-12-22 | 2024-01-11 | バイオジェン・エムエイ・インコーポレイテッド | Ｉｒａｋ４阻害剤としての２ｈ－インダゾール誘導体及び疾患の治療におけるそれらの使用 |
| WO2023283610A1 (en) * | 2021-07-07 | 2023-01-12 | Biogen Ma Inc. | Compounds for targeting degradation of irak4 proteins |
-
2023
- 2023-02-13 KR KR1020247003338A patent/KR20240051921A/ko active Pending
- 2023-02-13 EP EP23704963.0A patent/EP4479137A1/en active Pending
- 2023-02-13 PE PE2024001785A patent/PE20242100A1/es unknown
- 2023-02-13 CR CR20240383A patent/CR20240383A/es unknown
- 2023-02-13 CA CA3250704A patent/CA3250704A1/en active Pending
- 2023-02-13 WO PCT/EP2023/053416 patent/WO2023152349A1/en not_active Ceased
- 2023-02-13 AU AU2023218575A patent/AU2023218575A1/en active Pending
- 2023-02-13 IL IL314800A patent/IL314800A/en unknown
- 2023-02-13 JP JP2024505444A patent/JP7555519B2/ja active Active
- 2023-02-13 CN CN202380015865.2A patent/CN118591536A/zh active Pending
- 2023-02-13 MX MX2024009843A patent/MX2024009843A/es unknown
- 2023-02-14 TW TW112105102A patent/TW202400574A/zh unknown
- 2023-02-14 AR ARP230100328A patent/AR128506A1/es unknown
- 2023-02-14 UY UY0001040145A patent/UY40145A/es unknown
-
2024
- 2024-03-21 US US18/612,156 patent/US12240832B2/en active Active
- 2024-07-31 DO DO2024000148A patent/DOP2024000148A/es unknown
- 2024-08-12 CL CL2024002402A patent/CL2024002402A1/es unknown
- 2024-09-06 CO CONC2024/0012172A patent/CO2024012172A2/es unknown
- 2024-09-10 JP JP2024156852A patent/JP2025020096A/ja active Pending
-
2025
- 2025-02-07 US US19/047,789 patent/US20250368613A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7555519B2 (ja) | 2024-09-24 |
| IL314800A (en) | 2024-10-01 |
| DOP2024000148A (es) | 2024-09-15 |
| AR128506A1 (es) | 2024-05-15 |
| CA3250704A1 (en) | 2023-08-17 |
| WO2023152349A1 (en) | 2023-08-17 |
| US20240300923A1 (en) | 2024-09-12 |
| US20250368613A1 (en) | 2025-12-04 |
| CL2024002402A1 (es) | 2025-01-17 |
| CO2024012172A2 (es) | 2024-09-30 |
| AU2023218575A1 (en) | 2024-09-19 |
| CR20240383A (es) | 2024-11-22 |
| JP2024529501A (ja) | 2024-08-06 |
| KR20240051921A (ko) | 2024-04-22 |
| PE20242100A1 (es) | 2024-10-28 |
| US12240832B2 (en) | 2025-03-04 |
| CN118591536A (zh) | 2024-09-03 |
| TW202400574A (zh) | 2024-01-01 |
| EP4479137A1 (en) | 2024-12-25 |
| UY40145A (es) | 2023-08-15 |
| JP2025020096A (ja) | 2025-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39561A (es) | Inhibidores de IRAK4 | |
| CO2024010774A2 (es) | Inhibidor del inflamosoma nlrp3 y uso del mismo | |
| MX2025001036A (es) | Composicion farmaceutica que comprende un inhibidor de kras g12d | |
| MX2021009276A (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2. | |
| NO20061432L (no) | N3 alkylerte benzimidazolederivater som MEK-inhibitorer | |
| CO2024003923A2 (es) | Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t | |
| MA33886B1 (fr) | Dérivés substitués d'acide carbamoylméthylamino-acétique utilisés comme nouveaux inhibiteurs de nep | |
| MX2012014387A (es) | Dispersiones solidas que contienen inhibidores de cinasa. | |
| CO2024012172A2 (es) | Inhibidores de irak4 | |
| PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
| MA33364B1 (fr) | Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine | |
| PE20110943A1 (es) | Formulacion oral solida de alisquireno | |
| CO2025007341A2 (es) | Inhibidor del inflamosoma nlrp3 y uso de este | |
| MX2022005732A (es) | Derivado de amida y metodo de preparacion para el mismo y uso del mismo en medicina. | |
| AR049578A1 (es) | Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas | |
| CY1115623T1 (el) | Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ | |
| CL2022002817A1 (es) | Inhibidores de replicación del virus de inmunodeficiencia humana | |
| DOP2022000054A (es) | Inhibidor de irak y método de preparación para el mismo y uso del mismo | |
| MX2024002552A (es) | Inhibidor del antigeno de membrana prostatica especifico y uso farmaceutico del mismo. | |
| MX2023014722A (es) | Forma cristalina de tolebrutinib y método de preparación y su uso. | |
| DOP2025000046A (es) | Inhibidores de topoisomerasa-1 derivados de exatecán composiciones farmacéuticas y sus usos | |
| CO2024003094A2 (es) | Compuesto imidazocíclico y aplicación del mismo | |
| CO2024010726A2 (es) | Compuestos heterocíclicos y métodos de uso | |
| MX2025007935A (es) | Nuevos inhibidores reversibles de dpp1 y usos de estos | |
| EA201000701A1 (ru) | 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465 |